Equities analysts expect Can-Fite Biopharma Ltd (NASDAQ:CANF) to post ($0.80) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Can-Fite Biopharma’s earnings. Can-Fite Biopharma reported earnings of ($0.90) per share during the same quarter last year, which suggests a positive year over year growth rate of 11.1%. The business is expected to report its next quarterly earnings report on Friday, August 30th.
On average, analysts expect that Can-Fite Biopharma will report full-year earnings of ($1.49) per share for the current year. For the next fiscal year, analysts forecast that the firm will post earnings of ($0.32) per share. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Can-Fite Biopharma.
Can-Fite Biopharma (NASDAQ:CANF) last announced its quarterly earnings results on Wednesday, May 29th. The company reported ($1.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.94) by $0.74. The business had revenue of $0.30 million for the quarter.
Separately, HC Wainwright reissued a “buy” rating on shares of Can-Fite Biopharma in a report on Tuesday, March 26th.
Shares of CANF traded up $0.06 during midday trading on Thursday, reaching $3.10. 204,751 shares of the stock were exchanged, compared to its average volume of 126,536. Can-Fite Biopharma has a twelve month low of $2.66 and a twelve month high of $25.95. The firm has a 50 day moving average of $2.95.
About Can-Fite Biopharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.
Read More: How to start trading in the forex market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Can-Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.